How do you treat patients with sensitizing EGFR mutations who progress on osimertinib with small cell transformation, but with persistent EGFR mutation detected in the peripheral blood or tumor?
Is there a role for attempting to continue EGFR inhibition in addition to chemotherapy for small cell lung cancer?